Resolution of sickle cell crisis following administration of amiodarone

Keywords

amiodarone, sickle cell disease, anemia, erythrocytes

Abstract

Sickle cell disease is a prevalent hematologic condition, but some of the factors that lead to erythrocyte sickling are not fully known. A 58-year-old male patient with a history of sickle cell disease (SCD) and paroxysmal atrial fibrillation was transferred from an outside hospital for further management of refractory sickle cell crisis with acute chest syndrome. Before transfer, the patient received antibiotics and multiple packed red blood cell (pRBC) transfusions, with minimal effect on symptoms or anemia. After transfer, the patient developed rapid supraventricular tachycardia and atrial fibrillation (rates >160) with a drop in blood pressure. He was started on IV amiodarone. His heart rate was subsequently better controlled and converted to sinus rhythm the following day. Three days following initiation of amiodarone, the patient, with a hemoglobin count of 6.4 g/dl, required one additional unit of pRBC. On the fourth day, the patient’s hemoglobin count rose to 9.4 g/dl, and he reported a marked improvement in symptoms. The improvements in symptoms and hemoglobin count were sustained, and the patient was discharged two days later. This remarkable improvement in anemia and symptoms triggered a search for potential causes. Amiodarone is a complex drug shown to have effects on multiple cell types, including erythrocytes. A recent preclinical study demonstrated reduced sickling and improved anemia in a murine model of SCD. This case report raises the possibility that amiodarone may have contributed to the rapid improvement in anemia and should be further explored in clinical trials.

VIEW THE ENTIRE ARTICLE

References

  • Savitt TL, Goldberg MF. Herrick’s 1910 case report of sickle cell anemia. The rest of the story. JAMA 1989;261:266-71.
  • Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E. et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-6.
  • Reinhart WH, Rohner F. Effect of amiodarone on erythrocyte shape and membrane properties. Clin Sci (Lond) 1990;79:387-91.
  • Piccoli E, Nadai M, Caretta CM, Bergonzini V, Del Vecchio C, Ha HR. et al. Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype. Biochem Pharmacol 201;82:1234-49.
  • Venugopal J, Wang J, Guo C. et al. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease. Sci Rep 2020;10:16514.
  • Venugopal J, Wang J, Guo C. et al. Amiodarone improves anemia in a murine model of sickle cell disease and is associated with increased erythrocyte bis(monoacylglycerol) phosphate. Sci Rep 2022;12:16437.
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
  • Views: 418
    HTML downloads: 30
    PDF downloads: 379


    Published: 2023-05-12
    Issue: 2023: Vol 10 No 6 (view)


    How to cite:
    1.
    Silaghi P, Eitzman DT. Resolution of sickle cell crisis following administration of amiodarone. EJCRIM 2023;10 doi:10.12890/2023_003879.